Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
Public ClinicalTrials.gov record NCT03842696. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Multi-Center Trial of Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
Study identification
- NCT ID
- NCT03842696
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Enrollment
- 43 participants
Conditions and interventions
Conditions
- Acute Leukemia in Remission
- Chronic Myelogenous Leukemia - Chronic Phase
- Chronic Myelogenous Leukemia, Accelerated Phase
- Chronic Myelogenous Leukemia, Blastic Phase
- Diffuse Large B Cell Lymphoma
- Follicular Lymphoma
- Graft Vs Host Disease
- Graft-versus-host-disease
- Hematologic Diseases
- Mantle Cell Lymphoma
- Myelodysplastic Syndromes
- Non Hodgkin Lymphoma
Interventions
- Blood and Marrow Transplant (BMT) Procedure
- Cyclophosphamide Drug
- Methotrexate Drug
- Mycophenolate Mofetil (MMF) Drug
- Tacrolimus (or cyclosporine) Drug
- Vorinostat Drug
Procedure · Drug
Eligibility (public fields only)
- Age range
- 3 Years to 39 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 3, 2020
- Primary completion
- Jul 29, 2025
- Completion
- Mar 31, 2026
- Last update posted
- Jan 26, 2026
2020 – 2026
United States locations
- U.S. sites
- 7
- U.S. states
- 6
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Colorado | Aurora | Colorado | 80045 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| Indiana University Melvin and Bren Simon Comprehensive Cancer Center | Indianapolis | Indiana | 46202 | — |
| University of Michigan Health System | Ann Arbor | Michigan | 48109 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | 37232 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03842696, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 26, 2026 · Synced May 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03842696 live on ClinicalTrials.gov.